Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13687323 | 0.84 | MAPT (0.48) | SMN1; SMN2KDM4EALDH1A1HTT | |
| SCHEMBL31053557 | 0.81 | SMN1; SMN2 (0.68) | SMN1; SMN2KDM4EHSD17B10ALOX15TSHR | |
| SCHEMBL2825299 | 0.80 | MAPT (0.61) | SMN1; SMN2KDM4EALDH1A1USP2HTT | |
| SCHEMBL7527847 | 0.80 | KDM4E (0.62) | SMN1; SMN2KDM4EHSD17B10ALOX15TSHR | |
| SCHEMBL316264 | 0.80 | MAPT (0.67) | SMN1; SMN2KDM4EHSD17B10TSHRLMNA | |
| SCHEMBL25083131 | 0.79 | SMN1; SMN2 (0.66) | SMN1; SMN2KDM4EHSD17B10ALOX15TSHR | |
| SCHEMBL2568689 | 0.79 | SMN1; SMN2 (0.66) | SMN1; SMN2KDM4EHSD17B10ALOX15TSHR | |
| SCHEMBL427989 | 0.79 | SMN1; SMN2 (0.66) | SMN1; SMN2KDM4EHSD17B10ALOX15TSHR | |
| SCHEMBL4080193 | 0.78 | MAPT (0.64) | SMN1; SMN2KDM4EALDH1A1USP2 | |
| SCHEMBL4089872 | 0.78 | MAPT (0.64) | SMN1; SMN2KDM4EALDH1A1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 158 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3723754-B1 | IMIDAZO [1,2-C] QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES | MERCK SHARP & DOHME LLC (US) | 2026-05-13 | — | — | EP | disclosed |
| EP-3663291-B1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | KARYOPHARM THERAPEUTICS INC (US) | 2024-12-18 | — | — | EP | disclosed |
| US-11498923-B2 | Substituted imidazo[1,2-c]quinazolines as A2A antagonists | MERCK SHARP & DOHME LLC (US) | 2022-11-15 | — | — | US | disclosed |
| US-11498923-B2 | Substituted imidazo[1,2-c]quinazolines as A2A antagonists | MERCK SHARP & DOHME LLC (US) | 2022-11-15 | — | — | US | disclosed |
| US-11318120-B2 | Nuclear transport modulators and uses thereof | BIOGEN MA INC. (US) | 2022-05-03 | — | — | US | disclosed |
| US-20210251968-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | BIOGEN MA INC. (US) | 2021-08-19 | — | — | US | disclosed |
| US-20210053973-A1 | IMIDAZO[1,2-C]QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES | MERCK SHARP & DOHME CORP. (US) | 2021-02-25 | — | — | US | disclosed |
| US-20210053973-A1 | IMIDAZO[1,2-C]QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES | MERCK SHARP & DOHME CORP. (US) | 2021-02-25 | — | — | US | disclosed |
| US-10925859-B2 | Nuclear transport modulators and uses thereof | BIOGEN MA INC. (US) | 2021-02-23 | — | — | US | disclosed |
| CN-109316606-B | Preparation method of multi-stage pH-responsive mesoporous silica composite nanoparticles | 华南理工大学 | 2020-10-27 | — | — | CN | disclosed |
| US-20040077877-A1 | Indazole derivatives as JNK inhibitors and compositions and methods related thereto | SIGNAL PHARMACEUTICALS, INC. | 2004-04-22 | — | — | US | disclosed |
| EP-1313711-A2 | INDAZOLE DERIVATIVES AS JNK INHIBITORS | SIGNAL PHARMACEUTICALS, INC. (US) | 2003-05-28 | — | — | EP | disclosed |
| WO-2002010137-A9 | INDAZOLE DERIVATIVES AS JNK INHIBITORS | SIGNAL PHARM INC (US) | 2003-02-06 | — | — | WO | disclosed |
| US-20020103229-A1 | Indazole derivatives as JNK inhibitors and compositions and methods related thereto | SIGNAL PHARMACEUTICALS, LLC | 2002-08-01 | — | — | US | disclosed |
| WO-2002010137-A2 | INDAZOLE DERIVATIVES AS JNK INHIBITORS | SIGNAL PHARMACEUTICALS, INC. (US) | 2002-02-07 | — | — | WO | disclosed |
| CN-88102858-A | Process for preparing hydrazine derivatives useful as antihypertensive agents | — | 1988-12-14 | — | — | CN | disclosed |
| EP-0294258-A1 | Hydrazine derivatives, process for obtaining them and pharmaceutical composition containing them | Société anonyme: LES LABORATOIRES MERAM (FR) | 1988-12-07 | — | — | EP | disclosed |
| US-4593027-A | 3-aryl-7-chloro-3,4-dihydroacridine-1,9(2H,10H)-dione 1-oximes and 1-hydrazone derivatives, their salts, a process for their preparation, agents containing them and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1986-06-03 | — | — | US | disclosed |
| US-4548935-A | Dihydropyridine anti-ischaemic and anti-hypertensive agents, compositions and use | PFIZER INC. (US) | 1985-10-22 | — | — | US | disclosed |
| EP-0150939-A1 | Dihydropyridine anti-ischaemic and antihypertensive agents | Pfizer Limited (GB) | 1985-08-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077877-A1 | Indazole derivatives as JNK inhibitors and compositions and methods related thereto | MAP3K7, MAP3K1, MAP3K8 | SMN1; SMN2 4475/4885KDM4E 3665/4885HSD17B10 3346/4885 |
| US-20210251968-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | XPO1, XPO5, XPOT | SMN1; SMN2 765/4885KDM4E 2315/4885HSD17B10 1739/4885 |
| US-10925859-B2 | Nuclear transport modulators and uses thereof | XPO1, XPO5, XPOT | SMN1; SMN2 600/4885KDM4E 2490/4885HSD17B10 1804/4885 |
| US-11318120-B2 | Nuclear transport modulators and uses thereof | XPO1, XPO5, XPOT | SMN1; SMN2 765/4885KDM4E 2315/4885HSD17B10 1739/4885 |
| US-20020103229-A1 | Indazole derivatives as JNK inhibitors and compositions and methods related thereto | MAP3K7, MAP3K1, MAP3K8 | SMN1; SMN2 4475/4885KDM4E 3665/4885HSD17B10 3346/4885 |
| US-11498923-B2 | Substituted imidazo[1,2-c]quinazolines as A2A antagonists | ADORA2A, ADORA3, ADORA1 | SMN1; SMN2 418/4885KDM4E 3642/4885HSD17B10 4742/4885 |
| US-20210053973-A1 | IMIDAZO[1,2-C]QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES | ADORA2A, ADORA3, ADORA1 | SMN1; SMN2 431/4885KDM4E 3509/4885HSD17B10 4752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.